ArticleFrontiers in pediatrics2026
Neonatal-onset familial hemophagocytic lymphohistiocytosis type 2: a case report.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Familial hemophagocytic lymphohistiocytosis type 2 (FHL2) is a rare autosomal recessive disorder primarily caused by mutations in the perforin-1 (PRF1) gene, leading to immune system hyperactivation and multi-organ dysfunction. FHL2 typically presents in infancy, with neonatal onset being extremely rare and particularly difficult to recognize early due to substantial clinical overlap with sepsis. Given its rapid progression, early detection is critical for effective diagnosis and management. Case summary: This case report describes a neonate with FHL2 who presented on day 8 after birth with fever (peak 38.9 °C), abdominal distension, and dyspnea, accompanied by coagulation dysfunction, liver function abnormalities, and capillary leak syndrome. Despite intensive care, the patient's condition continued to deteriorate, with progression to disseminated intravascular coagulation (DIC), polyserositis, and multi-organ failure. Despite receiving intensive care and comprehensive treatment, the patient's condition continued to deteriorate. By day 7 of hospitalization, the patient was in a moribund state, and the family requested discharge against medical advice; the patient died after discharge. Postmortem genetic testing identified a homozygous c.145G > A mutation in the PRF1 gene, resulting in a substitution of aspartic acid to asparagine at position 49 of the encoded protein (p.Asp49Asn). This mutation has been documented as pathogenic in the Human Gene Mutation Database. Conclusion: FHL2 may present in the neonatal period with complex and variable clinical manifestations, frequently leading to misdiagnosis as neonatal sepsis or DIC. When neonates present with unexplained persistent fever, cytopenia, coagulation dysfunction, and multi-organ dysfunction that fails to respond to conventional anti-infective therapy, HLH should be included in the differential diagnosis, and genetic testing should be performed promptly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.